

Indication	Peri-operative and adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma. Suitable for fit patients only, with PS 0 - 1
Treatment Intent	Neo-adjuvant / adjuvant treatment
Frequency and number of cycles	Peri-operative: Every 14 days for 4 cycles before surgery and 4 cycles after surgery Adjuvant: Every 14 days for 8 cycles.
Monitoring parameters pre-treatment	<ul style="list-style-type: none"> • Monitor FBC, U&Es and LFT's at each cycle. • ECG prior to Cycle 1. • If neuts \geq 1.5 and PLT \geq100 continue with treatment. If neuts $<$1.5 or Plts $<$100 delay one week. • DPD testing: DPD testing must be undertaken in all patients before starting treatment; the result must be checked before treatment is started. • Hepatic and Renal Impairment: d/w consultant. <ul style="list-style-type: none"> ○ Docetaxel: Consider dose reduction of docetaxel in liver impairment. Docetaxel not recommended in severe hepatic impairment (serum bilirubin $>$ ULN and/or ALT/ AST $>$ 3.5 times the ULN associated with alkaline phosphatase $>$ 6 times the ULN). ○ 5-Fluorouracil consider reducing dose in moderate or severe hepatic impairment. ○ Oxaliplatin: If GFR is 30-50ml/min monitor renal function and consider dose reduction of oxaliplatin if toxicity. Omit oxaliplatin if CrCl $<$30ml/min. • Ensure dexamethasone pre-medication is prescribed and given to the patient at new patient chat. • Oxaliplatin • Reference should be made to 'Guidance on the Assessment and Management of Oxaliplatin Induced Neuropathy' available at: http://www.kentmedwaycancerguide.nhs.uk/medicines-and-prescribing-incorporating-sact-pathways/sact-pathways-guidelines-for-the-management-of-sact-induced-adverse-reactions-and-nursing/ • Dose reduction should be considered if any other grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to \leq grade 1 • Docetaxel hypersensitivity: Patients who have developed severe hypersensitivity reactions should not be re-challenged with docetaxel. • Common drug interactions (for comprehensive list refer to BNF/SPC): <ul style="list-style-type: none"> ○ Oxaliplatin: <ul style="list-style-type: none"> ➤ Caution is advised when oxaliplatin treatment is co-administered with other

Protocol No	UGI-058	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	2	Written by	M.Archer
Supersedes version	1	Checked by	C.Waters E.Parry
Date	31.03.2022	Authorising consultant (usually NOG Chair)	M.Cominos

	<p>medicinal products known to cause QT interval prolongation. In case of combination with such medicinal products, the QT interval should be closely monitored.</p> <ul style="list-style-type: none"> ➤ Caution is advised when oxaliplatin treatment is administered concomitantly with other medicinal products known to be associated with rhabdomyolysis. ○ Docetaxel: ➤ Concomitant use with medicines which induce, inhibit or are metabolised by cytochrome P450-3A (e.g. ciclosporin, ketoconazole and erythromycin) may affect levels of docetaxel, use with caution. ➤ Avoid concomitant use with strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin and ritonavir), if treatment cannot be avoided consider dose reduction of docetaxel and monitor patient closely for signs of toxicity.
Reference(s)	KMCC protocol UGI-058 V1

NB For funding information, refer to the SACT funding spreadsheet

Protocol No	UGI-058	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	2	Written by	M.Archer
Supersedes version	1	Checked by	C.Waters E.Parry
Date	31.03.2022	Authorising consultant (usually NOG Chair)	M.Cominos

Day	Drug	Dose	Route	Infusion Duration	Administration Details		
1	Ondansetron	<75yrs 16mg ≥75yrs 8mg	IV	15 min	NaCl 0.9% 50ml		
	DOCETAXEL	50mg/m²	IV	1 hr	Sodium Chloride 0.9% 250ml		
	Flush with 5% glucose before and after oxaliplatin administration						
	OXALIPLATIN	85mg/m²	IV	2 - 6hrs	250-500ml 5% glucose (to give a concentration between 0.2 mg/ml and 0.70 mg/ml)	Can be run concurrently	
	CALCIUM FOLINATE (calcium leucovorin)	200mg/m²	IV	2 hrs	Glucose 5% 250ml		
5-FLUOROURACIL	2600mg/m²	IV	24 hr pump	continuous infusion			
TTO	Drug	Dose	Route	Directions			
	Dexamethasone	8mg	PO	BD for 3 days starting one day prior to next cycle of chemotherapy			
	Metoclopramide	10mg	PO	3 times a day for 3 days, then 10mg up to 3 times a day as required. Do not take for more than 5 days continuously.			
	Filgrastim	300 micrograms or consider dose of 480 micrograms if patient > 80kg	SUB CUT	OD starting on day 4 for 5 days			

Protocol No	UGI-058	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	2	Written by	M.Archer	
Supersedes version	1	Checked by	C.Waters E.Parry	
Date	31.03.2022	Authorising consultant (usually NOG Chair)	M.Cominos	